Palvella Therapeutics Q2 net loss widens on higher expenses

Palvella Therapeutics

04/08/2026 13:08

Overview
US biopharmaceutical firm's Q2 net loss widened yr/yr amid higher R&D and admin expenses
Cash and short-term investments totaled $250.6 mln as of June 30, 2026

Result Drivers
R&D SPENDING - Co said higher research and development expenses were due to increased manufacturing activities, clinical development of QTORIN rapamycin for angiokeratomas, NDA submission costs, and increased headcount and consulting services
ADMIN COSTS - Co attributed higher general and administrative expenses to increased headcount and professional services related to operating as a publicly-traded company

Company press release: ID:nGNX3Twl3g

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$1.52
 
Q2 Net Loss
 
$21.87 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Palvella Therapeutics Inc is $225.00, about 59.8% above its August 3 closing price of $140.78

Reuters Recommended Reads
Aug 4 - Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand
Aug 3 - Ocular Therapeutix Q2 product revenue flat, net loss widens on higher spending
Aug 3 - TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)